Acculens Introduces NewVision SC Daily Wear Ortho-K Corneo-Scleral Lens

Acculens has introduced the NewVision SC Daily Wear Ortho-K Corneo-Scleral Lens, designed to temporarily reduce myopia of up to 5.00D in non-diseased eyes.

Designed to provide wear-time flexibility and comfort over traditional ortho-k lenses, NewVision lenses are ideal for patients who have myopic corrections of up to –5.00D who are interested in part-time daily wear lenses, Acculens shares. Crafted with Contamac Infinite material, NewVision lenses employ four distinct zones—the base curve/optic zone, reverse curve zone, corneal alignment curves, and corneal-scleral curves—to achieve a comfortable cornea-scleral lens for daily wear, according to the company.

All lenses have two key meridians, flat and steep, to create a dual elevation design beginning at the reverse curve, with a laser star marking to indicate the steeper of the two meridians. To maintain the orthokeratology effect of myopia reduction, Acculens shares that lens wear must be continued on a prescribed wearing schedule.

No fitting set is required, and NewVision lenses are 100% customizable and designed based on keratometry readings and corneal elevation. Compatible devices to determine corneal elevation data include the Eaglet Scleral Profiler, Pentacam with the Corneal Scleral Profile module, and Medmont topographer.

acculens.com 

OptiSource Releases Digital Pupilometer+ with Built-In Breath Shield

OptiSource has released a new Digital Pupilometer+ with Built-In Breath Shield.

The patent-pending shield flips down from the bottom of the pupilometer to provide protection for both the eyecare professional and patient, allowing the ECP to collect data without either party having to be concerned about airborne germs and other oral health issues, according to the company.

1-800-optisource.com 

Bausch + Lomb Launches Miebo in the U.S.

Bausch + Lomb announced the U.S. commercial launch of Miebo (perfluorohexyloctane ophthalmic solution) for the treatment of the signs and symptoms of dry eye disease (DED). Formerly known as NOV03, the water- and preservative-free perfluorohexyloctane ophthalmic solution is the first U.S. Food and Drug Administration (FDA)-approved treatment for DED that directly targets tear evaporation, according Bausch + Lomb. The FDA approved Meibo in May 2023.

A leading cause of DED, tear evaporation due to an altered tear lipid layer is often associated with the clinical signs of meibomian gland dysfunction. An unstable tear film can result in increased ocular surface desiccation, inflammation, and damage to the ocular surface, and Bausch + Lomb shares that Miebo is designed to reduce tear evaporation at the ocular surface.

bausch.com